A share price of Biogen Inc [BIIB] is currently trading at $222.75, up 1.38%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The BIIB shares have gain 4.33% over the last week, with a monthly amount glided 10.52%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Biogen Inc [NASDAQ: BIIB] stock has seen the most recent analyst activity on February 14, 2024, when Needham reiterated its Buy rating and also revised its price target to $300 from $305. Previously, Wells Fargo downgraded its rating to Equal Weight on February 14, 2024, and dropped its price target to $240. On January 24, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $276 on the stock. Raymond James upgraded its rating to a Outperform but $283 remained the price target by the analyst firm on December 07, 2023. HSBC Securities started tracking with a Buy rating for this stock on September 06, 2023, and assigned it a price target of $360. In a note dated July 27, 2023, Scotiabank initiated an Sector Outperform rating and provided a target price of $327 on this stock.
Biogen Inc experienced fluctuations in its stock price throughout the past year between $189.44 and $319.76. Currently, Wall Street analysts expect the stock to reach $290.63 within the next 12 months. Biogen Inc [NASDAQ: BIIB] shares were valued at $222.75 at the most recent close of the market. An investor can expect a potential return of 30.47% based on the average BIIB price forecast.
Analyzing the BIIB fundamentals
Trailing Twelve Months sales for Biogen Inc [NASDAQ:BIIB] were 9.29B which represents -5.62% decline. Gross Profit Margin for this corporation currently stands at 0.73% with Operating Profit Margin at 0.14%, Pretax Profit Margin comes in at 0.14%, and Net Profit Margin reading is 0.12%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.08 and Total Capital is 0.06. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.43.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 220.12 points at the first support level, and at 217.49 for the second support level. However, for the 1st resistance point, the stock is sitting at 224.15, and for the 2nd resistance point, it is at 225.54.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Biogen Inc [NASDAQ:BIIB] is 2.10. Also, the Quick Ratio is 1.32, while the Cash Ratio stands at 0.33. Considering the valuation of this stock, the price to sales ratio is 3.49, the price to book ratio is 2.13 and price to earnings (TTM) ratio is 27.82.
Transactions by insiders
Recent insider trading involved Singhal Priya, Head of Development, that happened on Apr 02 ’24 when 93.0 shares were sold. Head of Development, Singhal Priya completed a deal on Feb 22 ’24 to sell 262.0 shares. Meanwhile, Head of Development Singhal Priya sold 108.0 shares on Feb 16 ’24.
